Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A
SSZSE:00208211.00
CNY
-0.02
(-0.18%)
ISIN
CNE000001P94
Return %
Stock
S&P 500
1Y
-26.27
13.14
3Y
74.33
80.78
5Y
8.70
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Shou Ming Zhao
- Full Time Employees
- 1,348
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 28, Baizhang North Road Taizhou ZH China 317500
- IPO Date
- Nov 20, 2006
- Website
- wepon.com.cn
- Similar Companies
- Business
- Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices. Its main products include modern traditional Chinese medicines, chemical raw materials, and chemical preparations such as ginkgo biloba drip pills, huxerine injections, bromhexine hydrochloride tablets, sulpiride, clozapine tablets, chlorpromazine hydrochloride tablets, cimetidine tablets, omeprazole enteric capsules, and compound cloprenaline brohexine capsules. The company also manufactures medical devices, including orthopedic implantation devices (thoracolumbar fusion devices, inverted shoulder joints, unicondyl knee joints, movable intervertebral discs, knee replacement systems, independent fixed cervical fusion devices, modular hip joints) as well as disposable sterile medical polymer devices such as sterile syringes, self-destructing syringes, safety syringes with automatic needle retraction, disposable infusion devices, precision filter infusion sets, and TPE infusion sets. Additionally, Wanbangde provides medical device agency and maintenance services alongside integrated turnkey hospital engineering solutions. Operating primarily through the pharmaceutical production and sales segment and the medical equipment and personal equipment production and sale segment, the company targets treatment areas including cardiovascular and cerebrovascular diseases; nervous, respiratory, mental, and digestive system diseases. Wanbangde Pharmaceutical Holding Group serves markets both within China and internationally, with headquarters located in Wenling, Taizhou, Zhejiang Province, China. The company was founded in 2006 and is publicly listed on the Shenzhen Stock Exchange under ticker 002082.SZ. In the recent 1-2 years, Wanbangde has received regulatory nods for clinical trials of new products such as the WP107 oral solution. The company has been recognized with industry honors including the 2023 Outstanding Chinese Medicine Brand Enterprise, with certain products ranked among top non-prescription pharmaceutical products in China. It has also earned awards for scientific and technological achievements and ranks on Zhejiang’s High-tech Enterprise Top 500 Innovation Capabilities List for 2024. Wanbangde continues to expand its product pipeline and strengthen capabilities in both pharmaceuticals and medical devices, reflecting a strategic emphasis on innovation and integrated healthcare solutions in its core business sectors. Wanbangde Pharmaceutical Holding Group operates across China and overseas markets, with a product and service portfolio that spans traditional Chinese medicine, chemical pharmaceuticals, orthopedic implants, sterile medical consumables, and hospital engineering, making it a comprehensive healthcare supplier focused on improving treatment outcomes through an integrated offering of products and services.